Effect of Home-base Exercise With Conical-PEP Device on Physical Performance and Quality of Life in COPD

Summary

The aim of this study to investigate the efficacy of a home-base exercise program with a new conical PEP device on physical performance and health related quality of life in COPD patients.

Conditions

• Chronic Obstructive Pulmonary Disease

Interventions

DEVICE

A non-re-breathing face mask with conical-PEP device

Participant will use a non-re-breathing face mask with conical-PEP device during an interval endurance spot marching exercise.

OTHER

A home-base exercise program

Duration of the program is 8 weeks A frequency of exercise session is 3 to 5 sessions per week A content of each exercise session includes 1. Stretching exercise (shoulder, trunk and leg muscles) to warm up for 5 to 10 minutes 2. Interval endurance exercise using a spot marching movement for 30 to 40 minutes. In each phase of spot marching exercise, patients will perform the exercise from 0 to 3 or 4 score of 10 score of a modified dyspnea Borg scale, they will record exercise the exercise duration time. Then, they will be required to rest until a modified dyspnea Borg scale \< 1 score. Next, they will perform the next interval of spot marching exercise with the same protocol. 3. Stretching exercise (shoulder, trunk and leg muscles) to cool down for 5 to 10 minutes

OTHER

Health education

Health education include 1. Knowledge of COPD disease 2. Smoking status and smoking cessation 3. Medication correctly 4. Self dyspnea management 5. Basic nutrition for COPD

OTHER

ฺBreathing strategies for self secretion clearance

Using a modified active cycle breathing technique (mACBT) include 1. Control breathing 2. Pursed lip breathing (PLB) 3. Slow inhale with sustain thoracic expansion for 3 sec and exhale with PLB technique 4. Force expiratory technique (FET) with low to medium lung volume 5. Huffing or coughing

DRUG

The medication following the COPD GOLD guidelines (2015)

Patients will receive medications following the COPD GOLD guidelines (2015). The medication names were listed below 1. Bata 2 agonist (short acting); Salbutamol (oral or inhaler), Terbutaline (oral) 2. Bata 2 agonist (long acting); Bambuterol (oral), Procaterol (oral), Salmeterol (inhaler), Formoterol (inhaler) 3. Xanthine derivative (sustained release theophylline) 4. Anticholinergic; Tiotropium(inhaler), Ipratropium bromide (inhaler) 5. Corticosteroids; Beclomethasone (inhaler), Budesonide(inhaler), Fluticasone(inhaler) 6. Combined anticholinergic+ Beta 2-agonist; Ipratropium+fenoterol (inhaler), Ipratropium+salbutamol (inhaler) 7. Combined Beta 2-agonist+ corticosteroids; Formoterol+ Budesonide(inhaler), Salmeterol+ Fluticasone(inhaler)

Sponsors & Collaborators

• Thailand Research Fund

  collaborator OTHER

• Khon Kaen University

  lead OTHER

Principal Investigators

• Chulee U Jones, Ph.D., PT · Khon Kaen University

• Chatchai Phimphasak, M.Sc, PT · Khon Kaen University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

35 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-10-31

Primary Completion

2018-01-31

Completion

2018-05-31

Countries

• Thailand

Study Locations